Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1999-08-05
2000-10-17
Huang, Evelyn Mei
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514293, 514183, 51421205, 540479, 540583, 544328, 544331, 544333, 546 82, 546 87, 546113, A61K 31437, C07D47104, C07D47114, A61P 2524
Patent
active
061332828
ABSTRACT:
Disclosed are compounds of the formula: ##STR1## wherein Ar is optionally substituted aryl or heteroaryl
REFERENCES:
patent: 4605642 (1986-08-01), Rivier
patent: 5063245 (1991-11-01), Abreu
patent: 5644057 (1997-07-01), Yuan
patent: 5804685 (1998-09-01), Yuan
patent: 5847136 (1998-12-01), Yuan
Owens et al., "Physiology and Pharmacology of Corticotropin-releasing Factor," Pharm. Rev., Vo. 43, pp. 425-473 (1991).
Montgomery, et al. "The Use of Enamines I the Sythesis of Heterocycles," J. Het. Chem., vol. 9, pp. 1077-1079.
Zimmerman et al. "Pyrrolo[2,3-b]pyridines" Arch. Pharm. vol. 309, pp. 597-600.
Horvath Raymond F.
Hutchison Alan
Huang Evelyn Mei
Neurogen Corporation
Sarussi Steven J.
LandOfFree
Certain pyrrolopyridine derivatives; novel CRF1 specific ligands does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Certain pyrrolopyridine derivatives; novel CRF1 specific ligands, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Certain pyrrolopyridine derivatives; novel CRF1 specific ligands will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-469288